Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table

Pulmonary Pharmacology and Therapeutics

Volumn 28, Issue 2, 2014, Pages 149-153

  Kornmann, Oliver ^a   Watz, Henrik ^b   Fuhr, Rainard ^c   Krug, Norbert ^d   Erpenbeck, Veit J ^e   Kaiser, Guenther ^e  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b Member of the German Center for Lung Research   (Germany)

^c PAREXEL INTERNATIONAL   (United States)

^d FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bodyweight; IgE; Omalizumab; PK PD

Indexed keywords

IMMUNOGLOBULIN E; OMALIZUMAB; ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; ADVERSE DRUG REACTION; ALLERGIC ASTHMA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BODY WEIGHT; BRONCHITIS; CLINICAL ARTICLE; DISEASE EXACERBATION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; ELECTROCARDIOGRAM; FEMALE; GASTROENTERITIS; HEMATOMA; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIMB PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PARALLEL DESIGN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PRURITUS; RHINOPHARYNGITIS; SORE THROAT; TREATMENT DURATION; VITAL SIGN; VOMITING; ADOLESCENT; ASTHMA; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; IMMUNOLOGY; MIDDLE AGED; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOGLOBULIN E; MIDDLE AGED; PATIENT SELECTION; YOUNG ADULT;

EID: 84904115407     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2014.03.003     Document Type: Article

References (15)

1. Kuhl K., Hanania N.A. Targeting IgE in asthma. Curr Opin Pulm Med 2012, 18:1-5.
2. European Medicines Agency (EMA): Omalizumab (Xolair®) full prescribing information (EU). [accessed 13.04.13]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf.
3. Bousquet J., Cabrera P., Berkman N., Buhl R., Holgate S., Wenzel S., et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005, 60:302-308.
4. Corren J., Casale T.B., Lanier B., Buhl R., Holgate S., Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy 2009, 39:788-797.
5. Humbert M., Beasley R., Ayres J., Slavin R., Hébert J., Bousquet J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-316.
6. Holgate S.T., Chuchalin A.G., Hébert J., Lötvall J., Persson G.B., Chung K.F., et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004, 34:632-638.
7. Hochhaus G., Brookman L., Fox H., Johnson C., Matthews J., Ren S., et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003, 19:491-498.
8. Novartis data on file. Study 009 (INNOVATE).
9. Haselkorn T., Borish L., Miller D.P., Weiss S.T., Wong D.A. High prevalence of skin test positivity in severe or difficult-to-treat asthma. JAsthma 2006, 43:745-752.
10. Zielen S., Lieb A., De La Motte S., Wagner F., de Monchy J., Fuhr R., et al. Omalizumab protects against allergen-induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma. Int Arch Allergy Immunol 2013, 160:102-110.
11. Global Initiative for Asthma (GINA) Global strategy for asthma management and prevention 2011, [accessed 15.04.12]. http://www.ginasthma.org/.
12. Lowe P.J., Tannenbaum S., Gautier A., Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 2009, 68:61-76.
13. Strunk R.C., Bloomberg G.R. Omalizumb for asthma. NEngl J Med 2006, 354:2689-2695.
14. Rivière G.J., Yeh C.-M., Reynolds C.V., Brookman L., Kaiser G. Bioequivalence of a novel omalizumab solution for injection compared with the standard lyophilised powder formulation. JBioequiv Availab 2011, 3:144-150.
15. Slavin R.G., Ferioli C., Tannenbaum S.J., Martin C., Blogg M., Lowe P.J. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. JAllergy Clin Immunol 2009, 123:107-113.